FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904657085> ?p ?o ?g. }

• W2904657085 endingPage "164" @default.
• W2904657085 startingPage "164" @default.
• W2904657085 abstract "<h3>Importance</h3> In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. <h3>Objective</h3> To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. <h3>Design, Setting, and Participants</h3> This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. <h3>Interventions</h3> Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. <h3>Main Outcomes and Measures</h3> Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. <h3>Results</h3> The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (<i>P</i> = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95;<i>P</i> = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). <h3>Conclusions and Relevance</h3> Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT01099423" @default.
• W2904657085 created "2018-12-22" @default.
• W2904657085 creator A5010015430 @default.
• W2904657085 creator A5012800133 @default.
• W2904657085 creator A5013406375 @default.
• W2904657085 creator A5017136846 @default.
• W2904657085 creator A5017488456 @default.
• W2904657085 creator A5020692060 @default.
• W2904657085 creator A5027716206 @default.
• W2904657085 creator A5029542651 @default.
• W2904657085 creator A5032816632 @default.
• W2904657085 creator A5043348199 @default.
• W2904657085 creator A5049909021 @default.
• W2904657085 creator A5061157288 @default.
• W2904657085 creator A5062519984 @default.
• W2904657085 creator A5068678186 @default.
• W2904657085 creator A5068814576 @default.
• W2904657085 creator A5077514210 @default.
• W2904657085 creator A5081011064 @default.
• W2904657085 creator A5083765215 @default.
• W2904657085 creator A5084135027 @default.
• W2904657085 creator A5088390068 @default.
• W2904657085 date "2019-02-01" @default.
• W2904657085 modified "2023-10-11" @default.
• W2904657085 title "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib" @default.
• W2904657085 cites W1988038462 @default.
• W2904657085 cites W1994485684 @default.
• W2904657085 cites W2000366267 @default.
• W2904657085 cites W2003926480 @default.
• W2904657085 cites W2008244959 @default.
• W2904657085 cites W2021256410 @default.
• W2904657085 cites W2061414864 @default.
• W2904657085 cites W2072478300 @default.
• W2904657085 cites W2094351391 @default.
• W2904657085 cites W2099752220 @default.
• W2904657085 cites W2105937199 @default.
• W2904657085 cites W2116661424 @default.
• W2904657085 cites W2140659843 @default.
• W2904657085 cites W2141359162 @default.
• W2904657085 cites W2143813821 @default.
• W2904657085 cites W2145969161 @default.
• W2904657085 cites W2149456801 @default.
• W2904657085 cites W2156667045 @default.
• W2904657085 cites W2164317031 @default.
• W2904657085 cites W2415611423 @default.
• W2904657085 cites W2415766229 @default.
• W2904657085 cites W2480391546 @default.
• W2904657085 cites W2520690676 @default.
• W2904657085 cites W2797282777 @default.
• W2904657085 cites W2805060661 @default.
• W2904657085 cites W2977606681 @default.
• W2904657085 cites W4240925274 @default.
• W2904657085 cites W4292528167 @default.
• W2904657085 cites W4298269398 @default.
• W2904657085 doi "https://doi.org/10.1001/jamaoncol.2018.5543" @default.
• W2904657085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6439568" @default.
• W2904657085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30543350" @default.
• W2904657085 hasPublicationYear "2019" @default.
• W2904657085 type Work @default.
• W2904657085 sameAs 2904657085 @default.
• W2904657085 citedByCount "301" @default.
• W2904657085 countsByYear W29046570852017 @default.
• W2904657085 countsByYear W29046570852018 @default.
• W2904657085 countsByYear W29046570852019 @default.
• W2904657085 countsByYear W29046570852020 @default.
• W2904657085 countsByYear W29046570852021 @default.
• W2904657085 countsByYear W29046570852022 @default.
• W2904657085 countsByYear W29046570852023 @default.
• W2904657085 crossrefType "journal-article" @default.
• W2904657085 hasAuthorship W2904657085A5010015430 @default.
• W2904657085 hasAuthorship W2904657085A5012800133 @default.
• W2904657085 hasAuthorship W2904657085A5013406375 @default.
• W2904657085 hasAuthorship W2904657085A5017136846 @default.
• W2904657085 hasAuthorship W2904657085A5017488456 @default.
• W2904657085 hasAuthorship W2904657085A5020692060 @default.
• W2904657085 hasAuthorship W2904657085A5027716206 @default.
• W2904657085 hasAuthorship W2904657085A5029542651 @default.
• W2904657085 hasAuthorship W2904657085A5032816632 @default.
• W2904657085 hasAuthorship W2904657085A5043348199 @default.
• W2904657085 hasAuthorship W2904657085A5049909021 @default.
• W2904657085 hasAuthorship W2904657085A5061157288 @default.
• W2904657085 hasAuthorship W2904657085A5062519984 @default.
• W2904657085 hasAuthorship W2904657085A5068678186 @default.
• W2904657085 hasAuthorship W2904657085A5068814576 @default.
• W2904657085 hasAuthorship W2904657085A5077514210 @default.
• W2904657085 hasAuthorship W2904657085A5081011064 @default.
• W2904657085 hasAuthorship W2904657085A5083765215 @default.
• W2904657085 hasAuthorship W2904657085A5084135027 @default.
• W2904657085 hasAuthorship W2904657085A5088390068 @default.
• W2904657085 hasBestOaLocation W29046570851 @default.
• W2904657085 hasConcept C126322002 @default.
• W2904657085 hasConcept C126894567 @default.
• W2904657085 hasConcept C141071460 @default.
• W2904657085 hasConcept C143998085 @default.
• W2904657085 hasConcept C168563851 @default.
• W2904657085 hasConcept C197934379 @default.
• W2904657085 hasConcept C203092338 @default.
• W2904657085 hasConcept C2776694085 @default.

• next